<DOC>
	<DOCNO>NCT01657240</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy ophthalmic solution PRO-118 compare olopatadine hydrochloride ophthalmic solution allergic conjunctivitis .</brief_summary>
	<brief_title>Clinical Efficacy PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution Allergic Conjunctivitis</brief_title>
	<detailed_description>Allergic conjunctivitis inflammation tissue line eyelid ( conjunctiva ) due reaction allergy-causing substance . The main aim allergic conjunctivitis improve quality life patient . Antihistaminic medication commonly use treat allergic conjunctivitis symptom . The aim study compare clinical efficacy two ophthalmic solution contain one antihistaminic drug . A phase III randomize double-blind clinical trial conduct evaluate efficacy ophthalmic solution PRO-118 compare olopatadine hydrochloride ophthalmic solution allergic conjunctivitis . Patients randomize receive one treatments 21 day . Efficacy endpoint measure baseline 21 day treatment .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Provide inform consent Allergic conjunctivitis diagnosis Both gender Age 6 60 year Patients treatment 2 year prior study inclusion Patients one blind eye Visual acuity &lt; 20/40 eye Patients active ocular disease would interfere study interpretation Patients treatment medication could interfere study , contraindication medication use protocol Patients : diabetes mellitus , rheumatoid arthritis , hypertension , type cancer Patients history hypersensitivity contraindication drug use study Patients receive systemic topical treatment base antihistamine , corticosteroid immunomodulators Pregnant patient , risk pregnancy breastfeed Patients without birth control treatment Patients participate clinical trial last 90 day</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>